Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

The case for assessing the full value of new tuberculosis vaccines.

Gebreselassie N, Hutubessy R, Vekemans J, den Boon S, Kasaeva T, Zignol M.

Eur Respir J. 2020 Mar 20;55(3). pii: 1902414. doi: 10.1183/13993003.02414-2019. Print 2020 Mar. No abstract available.

PMID:
32198269
2.

Mapping the tuberculosis scientific landscape among BRICS countries: a bibliometric and network analysis.

Castor K, Mota FB, da Silva RM, Cabral BP, Maciel EL, de Almeida IN, Arakaki-Sanchez D, Andrade KB, Testov V, Vasilyeva I, Zhao Y, Zhang H, Singh M, Rao R, Tripathy S, Gray G, Padayatchi N, Bhagwandin N, Swaminathan S, Kasaeva T, Kritski A.

Mem Inst Oswaldo Cruz. 2020 Mar 16;115:e190342. doi: 10.1590/0074-02760190342. eCollection 2020.

3.

WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence.

Falzon D, Schünemann HJ, Zignol M, Mirzayev F, Kasaeva T.

Eur Respir J. 2020 Mar 5;55(3). pii: 1902325. doi: 10.1183/13993003.02325-2019. Print 2020 Mar. No abstract available.

PMID:
32139588
4.

Latent tuberculosis infection in children and adolescents in Russia.

Aksenova VA, Vasilyeva IA, Kasaeva TC, Samoilova AG, Pshenichnaya NY, Tyulkova TE.

Int J Infect Dis. 2020 Mar;92S:S26-S30. doi: 10.1016/j.ijid.2020.02.038. Epub 2020 Feb 27.

5.

Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries.

Al Abri S, Kasaeva T, Migliori GB, Goletti D, Zenner D, Denholm J, Al Maani A, Cirillo DM, Schön T, Lillebæk T, Al-Jardani A, Go UY, Dias HM, Tiberi S, Al Yaquobi F, Khamis FA, Kurup P, Wilson M, Memish Z, Al Maqbali A, Akhtar M, Wejse C, Petersen E.

Int J Infect Dis. 2020 Mar;92S:S60-S68. doi: 10.1016/j.ijid.2020.02.042. Epub 2020 Feb 27.

6.

Advances in clinical trial design: Weaving tomorrow's TB treatments.

Lienhardt C, Nunn A, Chaisson R, Vernon AA, Zignol M, Nahid P, Delaporte E, Kasaeva T.

PLoS Med. 2020 Feb 27;17(2):e1003059. doi: 10.1371/journal.pmed.1003059. eCollection 2020 Feb.

7.

Tuberculosis research questions identified through the WHO policy guideline development process.

Gebreselassie N, Falzon D, Zignol M, Kasaeva T.

Eur Respir J. 2019 Mar 18;53(3). pii: 1802407. doi: 10.1183/13993003.02407-2018. Print 2019 Mar. No abstract available.

PMID:
30886024
8.

A new tuberculosis vaccine: breakthrough, challenges, and a call for collaboration.

Vekemans J, Gebreselassie N, Zignol M, Friede M, Kasaeva T, Swaminathan S.

Lancet Infect Dis. 2019 Feb;19(2):123-125. doi: 10.1016/S1473-3099(19)30003-9. Epub 2019 Jan 30. No abstract available.

PMID:
30712831
9.

Back to the future, again: greater leadership, collaboration and accountability to accelerate progress to end TB.

Weil D, Marinkovic K, Kasaeva T.

BMC Med. 2018 Sep 19;16(1):172. doi: 10.1186/s12916-018-1165-9.

10.

Priorities for global political momentum to end TB: a critical point in time.

Kasaeva T, Baddeley A, Floyd K, Jaramillo E, Lienhardt C, Nishikiori N, Weil DE, Weyer K, Zignol M.

BMJ Glob Health. 2018 Mar 23;3(2):e000830. doi: 10.1136/bmjgh-2018-000830. eCollection 2018. No abstract available.

11.

Tuberculosis research and development: seeding the future.

Lienhardt C, Zumla A, Gebreselassie N, Frick M, Gray G, Kasaeva T, Raviglione M.

Lancet Respir Med. 2018 Apr;6(4):242-244. doi: 10.1016/S2213-2600(18)30050-X. No abstract available.

PMID:
29595503
12.

Tuberculosis makes it onto the international political agenda for health…finally.

Raviglione M, Uplekar M, Weil D, Kasaeva T.

Lancet Glob Health. 2018 Jan;6(1):e20-e21. doi: 10.1016/S2214-109X(17)30449-7. Epub 2017 Nov 15. No abstract available.

Supplemental Content

Loading ...
Support Center